

3. Pearce I, Simó R, Lövestam-Adrian M, et al. Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic review. *Diabetes Obes Metab.* 2019; 21(3):467-478.
4. Lin YC, Chang YH, Yang SY, et al. Update of pathophysiology and management of diabetic kidney disease. *J Formos Med Assoc.* 2018; 117(8):662-675.
5. American Diabetes Association. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes – 2024. *Diabetes Care.* 2024;47(Suppl 1):S231-243.
6. Zhelev Z, Peters J, Rogers M, et al. Test accuracy of artificial intelligence-based grading of fundus images in diabetic retinopathy screening: A systematic review. *J Med Screen.* 2023;30(3):97-112.
7. Pelikánová T, Bartoš V, et al. *Praktická diabetologie.* 6. vydání. Praha: Maxdorf Jessenius, 2018. ISBN 978-80-7345-559-0.
8. Bain SC, Klufas MA, Ho A, et al. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. *Diabetes Obes Metab.* 2019;21:454.
9. UKPDS Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). *BMJ* 1998;317:703-13.
10. American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes – 2024. *Diabetes Care.* 2024; 47:S179.
11. Chung YR, Park SW, Choi SY, et al. Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy. *Cardiovasc Diabetol.* 2017;16:4.
12. Keech AC, Mitchell P, Summaman PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. *Lancet* 2007;370:1687.
13. ACCORD Study Group, ACCORD Eye Study Group, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. *N Engl J Med.* 2010; 363:233.
14. Altaf QA, Dodson P, Ali A, et al. Obstructive sleep apnea and retinopathy in patients with type 2 diabetes. A longitudinal study. *Am J Respir Crit Care Med.* 2017;196:892-900.
15. Widyaputri F, Rogers SL, Kandasamy R et al. Global estimates of diabetic retinopathy prevalence and progression in pregnant women with preexisting diabetes: a systematic review and meta-analysis. *JAMA Ophthalmol.* 2022;140:486-494.
16. de Boer IH; DCCT/EDIC Research Group. Kidney disease and related findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. *Diabetes Care.* 2014;37:24-30.
17. Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet.* 2020;395(10225):709-733.
18. Fox CS, Matsushita K, Woodward M, et al. Chronic Kidney Disease Prognosis Consortium, Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. *Lancet* 2012;380:1662-1673.
19. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney disease: Challenges, progress and possibilities. *Clin J Am Soc Nephrol.* 2017;12(12):2032-2045.
20. National Kidney Foundation: KDOQI clinical practice guideline for diabetes and CKD: 2012 update. *Am J Kidney Dis.* 60:850-886.
21. Pelikánová T, Viklický O, Rychlík I, et al. Doporučené postupy při diabetickém onemocnění ledvin 2021.
22. DCCT/EDIC research group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. *Lancet Diabetes Endocrinol.* 2014;2:793-800.
23. UK Prospective Diabetes Study. (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet.* 1998;352:837.
24. Papadimitrou V, Lovato L, Doumas M, et al. ACCORD Study Group. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. *Kidney Int.* 2015;87:649-659.
25. de Boer IH, Bangalore S, Benetos A, et al. Diabetes and hypertension: a position statement by the American Diabetes Association. *Diabetes Care.* 2017;40:1273-1284.
26. Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med.* 2001;345:861-869.
27. American Diabetes Association. 11. Chronic kidney disease and risk management: Standards of Care in Diabetes – 2024. *Diabetes Care.* 2024;47(Suppl 1):S219-230.
28. Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. *J Am Col Cardiol.* 2018;72:1845-1855.
29. Yarbeygi H, Butler AE, Atkin SL, et al. Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways. *J Cell Physiol.* 2018;234:223-230.
30. Shaman AM, Bain SC, Bakris GL, et al. Effects of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. *Circulation.* 2022;145:575-585.
31. McGuire DK, Shih WJ, Consentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. *JAMA Cardiol.* 2021;6:148-158.
32. Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. *Circulation.* 2019;139:2022-2031.
33. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. *NEJM* 2024;391:109-121.
34. Agarwal R, Filippatos G, Pitt B, et al. FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. *Eur Heart J.* 2022;43:474-484.
35. Liu X, Xu Y, An M, et al. The risk factors for diabetic peripheral neuropathy: A meta-analysis. *PLoS One.* 2019;14:e0212574.
36. Lácigová S, Rušavý Z, Jirkovská A, Škrha J. Doporučený postup diagnostiky a léčby diabetické neuropatie (2016).
37. Ang L, Jaiswal M, Martin C, et al. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. *Curr Diab Rep.* 2014;14:528.
38. Callaghan BC, Little AA, Feldman EL, et al. Enhanced glucose control for preventing and treating diabetic neuropathy. *Cochrane Database Syst Rev.* 2012;6:CD007543.
39. ACCORD Study Group. Effect of intensive treatment of hyperglycemia on microvascular outcomes in type 2 diabetes: an analysis of ACCORD randomised trial. *Lancet.* 2010;376(9739):419-430.
40. Jirkovská A., et al. Syndrom diabetické nohy – Prevence, diagnostika a terapie. *Geum* 2022. ISBN 978-80-87969-61-8.
41. Baicus C, Purcarea A, von Elm E, et al. Alpha-lipoic acid for diabetic peripheral neuropathy. *Cochrane Database Syst Rev.* 2024;CD012967.